USA – BD (Becton, Dickinson and Company), a global leader in medical technology, has launched the BD Intraosseous (IO) Vascular Access System, a cutting-edge device designed to enhance emergency medical care.
This new system provides healthcare professionals with an efficient method to administer fluids and medications through the bone marrow when conventional intravenous (IV) access is not feasible, offering critical support in urgent care scenarios.
The BD IO Vascular Access System stands out for its versatility and advanced safety features, making it suitable for use in both adult and pediatric patients across various emergency care settings.
The system’s primary innovation lies in its powered driver, equipped with a rechargeable battery that outlasts other non-rechargeable options on the market, reportedly lasting up to 12 times longer.
The driver also includes a multi-light battery indicator for real-time battery status checks, ensuring reliable operation in time-sensitive situations.
Eric Borin, president of Medication Delivery Solutions at BD, highlighted the company’s focus on life-saving innovations: “This system builds on BD’s commitment to improving patient outcomes, ensuring safe and efficient medication delivery with a high success rate.”
Safety and convenience at the forefront
BD’s system integrates several features that distinguish it from other intraosseous devices.
Notably, the extension set can be attached before placement, streamlining the procedure, and it incorporates passive needle tip safety mechanisms to minimize the risk of needlestick injuries.
With five needle lengths available, the system can be adapted to various patient needs, further enhancing its application in diverse medical scenarios.
The BD IO System is now available for purchase in the United States, promising a solution with less than a 1% complication rate and double the success rate for placement compared to traditional peripheral IVs or central venous catheters.
This new approach is expected to set a new standard in emergency medicine, providing an invaluable tool for healthcare professionals dealing with critically ill patients.
BD’s broader strategic moves
This product launch is part of BD’s broader strategy to maintain its strong position in the healthcare market.
The company, which employs over 70,000 people globally, continues to focus on advancing medical technologies, diagnostics, and care delivery to support the medical community and enhance clinical efficiency.
In its recent fiscal third quarter, BD reported a 5.2% organic revenue growth with earnings per share (EPS) reaching US $3.50, marking an 18% increase from the previous year.
Despite a slight revision in its organic growth guidance to between 5% and 5.25%, the company raised its EPS forecast for fiscal 2024 to a range of US $13.05 to US $13.15.
Addressing market challenges and opportunities
BD is proactively navigating the challenges within the medical technology sector, including competitive pressures and product litigation.
The company has settled a significant portion of its hernia product lawsuits, reducing uncertainty for its stakeholders.
Additionally, BD has strengthened its portfolio with strategic acquisitions, such as the Edwards Lifesciences Critical Care product group, now operating under BD Advanced Patient Monitoring.
This acquisition is aimed at enhancing BD’s smart, connected care solutions with advanced patient monitoring technologies powered by artificial intelligence.
Additionally, BD, in collaboration with Hamilton Robotics, introduced a new series of high-throughput, robotics-compatible reagent kits designed to automate and standardize the preparation of genetic material for sequencing.
